-- Pipeline focus will prioritize programs in immunology, including REZPEG and several immunology research programs -- -- Development of NKTR-255 in diffuse large B-cell lymphoma and bladder cancer to ...

ROCHESTER, N.Y. — One of Rochester’s largest employers, Paychex, is cutting its local workforce. The payroll company confirms what it calls a “reprioritization” of the company. A spokesperson for the ...

One of Rochester’s largest employers, Paychex, Inc., laid off some employees last week. In an emailed statement, the company confirmed the move, writing: “We are continuously reprioritizing roles ...

On Friday, Johnson & Johnson (NYSE:JNJ) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults ...

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the strategic ...

I rate Rocket Pharmaceuticals a hold, given its strategic shift to late-stage AAV cardiovascular therapies and disciplined capital allocation. The company is cutting costs, reducing staff by 30%, and ...

Cellectar Biosciences (CLRB) announces a strategic update on its clinical development programs for its proprietary phospholipid ether drug conjugate platform that delivers a broad array of therapeutic ...

The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of Allocetra TM as an innovative, ...

CAMBRIDGE, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a ...

One of the foundational impacts of the past several years has been what we’ve defined as “The Great Reprioritization”: how the pandemic and work from home facilitated a pivot in how people choose to ...